Fenwick Represents Augmedix in Raising Additional $19 Million in Series B Funding

Fenwick & West represented Augmedix, a company turning natural clinician-patient conversation into medical documentation, in real-time, so that clinicians can focus on patient care, in raising an additional $19 million in Series B funding that includes investments from Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments and others.

The company will use this fresh funding to accelerate product development, including automation capabilities, and to strategically scale its technology-enabled service across health systems and private clinics nationwide. More information about the financing can be obtained from the company’s announcement.

The Fenwick transaction team included corporate partner Michael Esquivel and associates Malcolm Katz, Nam Kim and Shweta Kumar.